Study to understand the characteristics, treatment patterns and outcomes in patients with Neovascular Age related macular degeneratio

Not Applicable

Conditions: Health Condition 1: H55-H57- Other disorders of eye and adnexa

Registration Number: CTRI/2020/12/029822

Lead Sponsor: ovartis Healthcare Pvt Ltd

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Open to Recruitment

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

Newly diagnosed nAMD patients

Patients (male or female) aged >=50 years of age at Index date

Patients diagnosed with nAMD in at least one eye

Patients with VA/OCT assessments at both baseline, Month 12 and Month 24

Patients treated with intravitreal injection of anti-VEGF (received at least one anti-VEGF injection during the post-index follow-up period and at least 2 visits with OCT in between Months 0-12).

Patients with minimum follow-up period of 24 months. (received at least one anti-VEGF injection and at least 1 visit with OCT in between Months 13-24)

Exclusion Criteria

Patients with dry AMD, geographic atrophy and other retinal diseases

Patients who were part of any other trial/ study

Patients undergoing additional ocular treatment along with Anti VEGF agents will be excluded.

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Association between anatomical outcomes (presence /absence) at Month 12 and changes in functional outcome from baseline to Month 12 will be investigated for the following endpoints: <br/ ><br>Anatomical outcomes at Month 12 <br/ ><br>IRF (presence / absence) <br/ ><br>SRF (presence / absence) <br/ ><br>Sub-RPE (presence/ absence) <br/ ><br>Functional outcomes at baseline and Month 12 <br/ ><br>VA change from baseline (in ETDRS letters) <br/ ><br>Timepoint: 12 months <br/ ><br>

Secondary Outcome Measures

Name	Time	Method
To evaluate mean change in BCVA after the start of anti- VEGF therapy at Months 3, 6, 12, 18 and 24 as measured by ETDRS letters gained or lost.Timepoint: Months 3, 6, 12, 18 and 24